Inclusion of the Risk Score in Decision Making of Valvular Heart Disease

被引:1
|
作者
Casalino, Ricardo [1 ]
Grinberg, Max [1 ]
机构
[1] InCor, Sao Paulo, Brazil
关键词
SOCIETY;
D O I
10.1590/S0066-782X2012000600018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clinical facts and numerical data support interpretations of quality of life and survival in patients with valvular heart disease. Such data are useful in decision making regarding the interruption of natural history and replacement by a hemodynamic post-correction history. Interdisciplinary competence and expertise are required to maximize the necessary and possible results. However, the ideal of recommendations to achieve the highest degree of therapeutic satisfaction by patients with valvular heart disease is influenced by a set of variables, related in part to the specifications of the patient, and part to the limitations of methods. The rationale of the risk score validated for multiple markers is the addition of quantitative accuracy to the clinical assessment based on the heterogeneity of individual experience and intuition. In this context, the use of risk scores to predict postoperative mortality are useful tools, easy to apply and that gives us objective data on the patient's situation. None of the available tools (EuroSCORE, STS score and Ambler Score) used in healthcare has been validated has in our population.
引用
收藏
页码:E102 / E104
页数:3
相关论文
共 50 条
  • [41] Valvular heart disease
    Sirois, DA
    Fatahzadeh, M
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 2001, 91 (01): : 15 - 19
  • [42] Valvular heart disease
    Drochner, U
    Mehnert, F
    RADIOLOGE, 1996, 36 (12): : 995 - 996
  • [43] Valvular heart disease
    Rahimtoola, SH
    Frye, RL
    CIRCULATION, 2000, 102 (20) : 24 - 33
  • [44] Valvular heart disease
    Carabello, BA
    Crawford, FA
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (01): : 32 - 41
  • [46] Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
    Cutter, David J.
    Schaapveld, Michael
    Darby, Sarah C.
    Hauptmann, Michael
    van Nimwegen, Frederika A.
    Krol, Augustinus D. G.
    Janus, Cecile P. M.
    van Leeuwen, Flora E.
    Aleman, Berthe M. P.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (04):
  • [47] Valvular heart disease: new risk factors and new challenges
    Luscher, Thomas F.
    EUROPEAN HEART JOURNAL, 2017, 38 (16) : 1173 - 1176
  • [48] The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
    Tagen, Michael
    Mantuani, Daniel
    van Heerden, Liron
    Holstein, Alex
    Klumpers, Linda E.
    Knowles, Richard
    JOURNAL OF PSYCHOPHARMACOLOGY, 2023, 37 (09) : 876 - 890
  • [49] Antiphospholipid antibodies and the risk of thromboembolic events in valvular heart disease
    Bulckaen, HG
    Puisieux, FL
    Bulckaen, ED
    Di Pompeo, C
    Bouillanne, OM
    Watel, AA
    Fauchais, ALM
    De Groote, P
    Millaire, A
    MAYO CLINIC PROCEEDINGS, 2003, 78 (03) : 294 - 298
  • [50] Risk factors for coronary artery stenosis in valvular heart disease
    Orlowska-Baranowska, E
    Rawczynska-Englert, I
    JOURNAL OF HEART VALVE DISEASE, 1998, 7 (05): : 586 - 589